How to buy Merck-and-CoInc (MRK) shares in Australia
Learn how to easily invest in Merck-and-CoInc shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Merck & Co. Inc (MRK) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$81.6 after a previous close of US$81.32. During the day the price has varied from a low of USD80.765 to a high of USD81.8521. The latest price was USD81.38 (25 minute delay). Merck-and-CoInc is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Merck-and-CoInc
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Merck-and-CoInc. Find the share by name or ticker symbol: MRK. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Merck-and-CoInc reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$81.32, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Merck-and-CoInc, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Merck-and-CoInc. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Merck-and-CoInc key stats
- Compare share trading platforms
- Is Merck-and-CoInc stock a buy or sell?
- Merck-and-CoInc performance over time
- Is Merck-and-CoInc suitable for ethical investing?
- Are Merck-and-CoInc shares over-valued?
- Merck-and-CoInc's financials
- How volatile are Merck-and-CoInc shares?
- Does Merck-and-CoInc pay a dividend?
- Have Merck-and-CoInc shares ever split?
- Other common questions
Merck-and-CoInc stock price (NYSE:MRK)Use our graph to track the performance of MRK stocks over time.
Merck-and-CoInc shares at a glance
|52-week range||US$65.9822 - US$90.541|
|50-day moving average||US$78.2658|
|200-day moving average||US$77.0517|
|Dividend yield||US$2.56 (3.45%)|
|Earnings per share (TTM)||US$2.834|
Where to buy Merck-and-CoInc stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Merck-and-CoInc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Merck-and-CoInc price performance over time
|1 week (2022-01-21)||1.75%|
|1 month (2021-12-27)||6.28%|
|3 months (2021-10-28)||-5.97%|
|6 months (2021-07-28)||3.89%|
|1 year (2021-01-28)||9.45%|
|2 years (2020-01-28)||-1.04%|
|3 years (2019-01-28)||17.05%|
|5 years (2017-01-27)||38.22%|
Stocks similar to Merck-and-CoInc
Is Merck-and-CoInc under- or over-valued?
Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-CoInc's P/E ratio
Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Merck-and-CoInc shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Merck-and-CoInc's PEG ratio
Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.315. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$21.1 billion (£15.7 billion).
The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$52.6 billion|
|Operating margin TTM||33.82%|
|Gross profit TTM||US$34.6 billion|
|Return on assets TTM||12.13%|
|Return on equity TTM||26.04%|
|Market capitalisation||US$202 billion|
TTM: trailing 12 months
Merck-and-CoInc's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Merck-and-CoInc's total ESG risk score
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Merck-and-CoInc's environmental score
Environmental score: 3.15/100
Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Merck-and-CoInc's social score
Social score: 15.55/100
Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Merck-and-CoInc's governance score
Governance score: 12.65/100
Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Merck-and-CoInc's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||28.35|
|Total ESG percentile||47.16|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||3|
Merck-and-CoInc share dividends
Dividend payout ratio: 45.15% of net profits
Recently Merck-and-CoInc has paid out, on average, around 45.15% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.45% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.45% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.56 per share.
While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.
Merck-and-CoInc's most recent dividend payout was on 6 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2021 (the "ex-dividend date").
Have Merck-and-CoInc's shares ever split?
Merck-and-CoInc's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before the split, the next day you would own 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-CoInc shares which in turn could have impacted Merck-and-CoInc's share price.
Merck-and-CoInc share price volatility
Over the last 12 months, Merck-and-CoInc's shares have ranged in value from as little as US$65.9822 up to US$90.541. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4952. This would suggest that Merck-and-CoInc's shares are less volatile than average (for this exchange).
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck-and-CoInc in the news
Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
Factbox-Latest on the worldwide spread of the coronavirus
Private Advisory Group LLC Buys PowerShares QQQ Trust Ser 1, Lululemon Athletica Inc, FIRST TR ...
Frequently asked questions
More guides on Finder
Ubisoft’s NFT promise: ‘We won’t force our players to use Quartz’
In an exclusive interview with Finder, VP of Strategic Innovations Lab, Nicolas Pouard, spells out he future of Ubisoft's NFTs
2022 BMW 8 Series adds tweaked looks and extra tech ahead of mid-year launch
BMW Australia's 8 Series range is set to receive an update for 2022 with slightly refreshed styling and additional tech headlining its flagship luxury sports model.
Share market sell-off won’t change winners and losers
The current market sell-off is providing an opportunity for investors to pick up structural winners at a discount, two industry experts say.
Where to watch The Fallout online in Australia
Recovering from trauma is a lengthy process.
Ubisoft responds to angry NFT Digits and Quartz reaction – Interview
We talk to Nicolas Pouard, VP at Ubisoft's Strategic Innovations Lab, about the launch of Ubisoft Quartz and the Digits NFTs
Westpac expects to jack your mortgage up 6 times in 2 years
Find out why and how much it's likely to cost you.
The Great Australian Bake Off: How to watch the new season online
On your marks, get set, bake!
Travel insurance COVID: Does it cover hotel quarantine?
Hotel quarantine could cost you thousands unless you get the right travel insurance policy.
Lower credit card limits didn’t change my credit score… Why?
Your credit limits can affect your credit score and your chance of approval, but it's not always as simple as changing one to improve the other.
Ask an Expert